A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia

NCT07674810 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Zanubrutinib
DRUG: Obinutuzumab
DRUG: Sonrotoclax

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]